TY - JOUR
T1 - PK and PK/PD of doxycycline in drinking water after therapeutic use in pigs
AU - Prats, C.
AU - El Korchi, G.
AU - Giralt, M.
AU - Cristòfol, C.
AU - Peña, J.
AU - Zorrilla, I.
AU - Saborit, J.
AU - Pérez, Belén
PY - 2005/12/1
Y1 - 2005/12/1
N2 - A commercial doxycycline formulation was administered in drinking water to 12 pigs at the recommended dose of 10 mg/kg daily for 5 days. The mean plasma concentration at steady-state was 1.37 ± 1.21 μg/mL, which was reached at 68 ± 27.2 h postadministration. Absorption and elimination half-life values were 7.20 ± 2.42 and 7.01 ± 2.10 h, respectively. Most plasma concentrations during dosing were higher than the minimum inhibitory concentrations (MICs) described for the main porcine bacterial pathogens of the respiratory tract (Pasteurella multocida, Actinobacillus pleuropneumoniae, Bordetella bronchiseptica and Mycoplasma hyopneumoniae). It is concluded that when pigs were treated with doxycycline in drinking water at the recommended rate, therapeutically effective concentrations were achieved throughout the treatment period, supporting the clinical use of this tetracycline in the control of respiratory infections. However, inter-animal differences were marked. © 2005 Blackwell Publishing Ltd.
AB - A commercial doxycycline formulation was administered in drinking water to 12 pigs at the recommended dose of 10 mg/kg daily for 5 days. The mean plasma concentration at steady-state was 1.37 ± 1.21 μg/mL, which was reached at 68 ± 27.2 h postadministration. Absorption and elimination half-life values were 7.20 ± 2.42 and 7.01 ± 2.10 h, respectively. Most plasma concentrations during dosing were higher than the minimum inhibitory concentrations (MICs) described for the main porcine bacterial pathogens of the respiratory tract (Pasteurella multocida, Actinobacillus pleuropneumoniae, Bordetella bronchiseptica and Mycoplasma hyopneumoniae). It is concluded that when pigs were treated with doxycycline in drinking water at the recommended rate, therapeutically effective concentrations were achieved throughout the treatment period, supporting the clinical use of this tetracycline in the control of respiratory infections. However, inter-animal differences were marked. © 2005 Blackwell Publishing Ltd.
U2 - 10.1111/j.1365-2885.2005.00700.x
DO - 10.1111/j.1365-2885.2005.00700.x
M3 - Article
SN - 0140-7783
VL - 28
SP - 525
EP - 530
JO - Journal of Veterinary Pharmacology and Therapeutics
JF - Journal of Veterinary Pharmacology and Therapeutics
IS - 6
ER -